The FDA has approved Vimkunya, the first-ever vaccine to prevent chikungunya, a mosquito-borne viral disease. The vaccine is approved for people ages 12 and older and aims to prevent the severe joint pain, fever, rash, and fatigue caused by the virus.

Chikungunya is found in Asia, Africa, and the Americas, including popular tourist destinations. In 2024, there were 620,000 cases and over 200 deaths worldwide. The new vaccine provides a critical tool for protecting travelers and those living in affected regions.

How It Works

Vimkunya contains virus-like particles that resemble the chikungunya virus but do not cause infection. This helps the immune system develop antibodies, offering protection against future exposure.

Clinical trials involving over 3,500 people showed that 97.8% developed antibodies within 21 days of receiving the shot. The vaccine starts working within a week, with mild side effects such as injection site pain, fatigue, headache, and muscle pain.

Stay Safe from Chikungunya

• Get vaccinated if you plan to travel to affected regions.
• Use insect repellent and wear long sleeves to prevent mosquito bites.
• Remove standing water around your home to reduce mosquito breeding.

Bavarian Nordic, the vaccine manufacturer, will conduct further studies post-rollout. Always consult your healthcare provider before getting vaccinated, especially if you have allergies, a weak immune system, or are pregnant.

➡ Prevention is key! Protect yourself and your community from mosquito-borne diseases.